Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.41 USD | -3.33% | -6.35% | +44.25% |
May. 13 | Janney Starts TScan Therapeutics With Buy Rating, $11 Price Target | MT |
May. 13 | TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 7.01M | Sales 2025 * | 5.93M | Capitalization | 481M |
---|---|---|---|---|---|
Net income 2024 * | -131M | Net income 2025 * | -151M | EV / Sales 2024 * | 58.7 x |
Net cash position 2024 * | 68.9M | Net cash position 2025 * | 66.72M | EV / Sales 2025 * | 69.8 x |
P/E ratio 2024 * |
-6.84
x | P/E ratio 2025 * |
-6.37
x | Employees | 154 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.12% |
1 day | -3.33% | ||
1 week | -6.35% | ||
Current month | +8.94% | ||
1 month | +13.96% | ||
3 months | +24.41% | ||
6 months | +64.26% | ||
Current year | +44.25% |
Managers | Title | Age | Since |
---|---|---|---|
Gavin MacBeath
CEO | Chief Executive Officer | 54 | 18-11-30 |
Jason Amello
DFI | Director of Finance/CFO | 55 | Jan. 28 |
Justin McCue
CTO | Chief Tech/Sci/R&D Officer | - | Dec. 03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 76 | 19-02-28 | |
Stephen Biggar
BRD | Director/Board Member | 53 | 21-02-28 |
Gavin MacBeath
CEO | Chief Executive Officer | 54 | 18-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 8.41 | -3.33% | 220,362 |
24-05-23 | 8.7 | -8.52% | 122,477 |
24-05-22 | 9.51 | +2.48% | 195,538 |
24-05-21 | 9.28 | +0.98% | 299,857 |
24-05-20 | 9.19 | +2.34% | 250,731 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.25% | 481M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- TCRX Stock